GSK plc (NYSE:GSK) Shares Sold by Captrust Financial Advisors

Captrust Financial Advisors reduced its holdings in shares of GSK plc (NYSE:GSK) by 93.4% in the 4th quarter, HoldingsChannel reports. The fund owned 80,522 shares of the pharmaceutical company’s stock after selling 1,138,322 shares during the quarter. Captrust Financial Advisors’ holdings in GSK were worth $2,723,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Dorsey & Whitney Trust CO LLC lifted its stake in GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock worth $389,000 after purchasing an additional 278 shares during the last quarter. GC Wealth Management RIA LLC raised its holdings in GSK by 2.6% during the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock worth $474,000 after purchasing an additional 353 shares in the last quarter. Jacobi Capital Management LLC lifted its position in shares of GSK by 3.9% during the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock worth $352,000 after buying an additional 389 shares during the last quarter. Gladstone Institutional Advisory LLC boosted its holdings in shares of GSK by 3.4% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company’s stock valued at $413,000 after buying an additional 407 shares in the last quarter. Finally, CENTRAL TRUST Co grew its position in shares of GSK by 5.6% in the 4th quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company’s stock valued at $262,000 after buying an additional 414 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Morgan Stanley assumed coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. BNP Paribas initiated coverage on GSK in a research report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 target price for the company. Hsbc Global Res raised GSK to a “strong sell” rating in a research report on Monday, April 28th. Finally, StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 24th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $40.58.

GSK Stock Performance

NYSE GSK opened at $36.63 on Monday. The firm has a market cap of $75.58 billion, a P/E ratio of 23.04, a P/E/G ratio of 1.12 and a beta of 0.51. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.93. The business’s 50-day moving average price is $37.65 and its 200 day moving average price is $35.97. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.05. The company had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. The company’s revenue was up 2.1% on a year-over-year basis. During the same period last year, the business posted $0.43 EPS. On average, equities research analysts expect that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be given a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a yield of 4.60%. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, May 16th. GSK’s dividend payout ratio (DPR) is 86.60%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.